ストックスクリーナーアプリを入手
0.2802
0.43%
0.0011
前日終値:
$0.2791
開ける：
$0.288
24時間の取引高:
9,803
Relative Volume:
0.00
時価総額：
$3.95M
収益：
$19.57M
当期純損益:
$-25.12M
株価収益率:
-0.1212
EPS:
-2.3114
ネットキャッシュフロー:
$-19.71M
1週間 パフォーマンス:
-18.35%
1か月 パフォーマンス:
-32.43%
6か月 パフォーマンス:
-82.80%
1年 パフォーマンス:
-93.91%
1日の値動き範囲:
$0.2844
$0.2898
1週間の範囲:
$0.2604
$0.3219
52週間の値動き範囲:
$0.2604
$5.12
Vivos Therapeutics Inc Stock (VVOS) Company Profile
名前
Vivos Therapeutics Inc
セクター
電話
(866)908-4867
住所
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.2844 | 3.83M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
114.75 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.92 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.36 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.54 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc (VVOS) 最新ニュース
Vivos Therapeutics opens Henderson facility with $10M capacity - Investing.com
Vivos Therapeutics Opens Nevada Sleep Treatment Center - marketscreener.com
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment - The Manila Times
Vivos Therapeutics opens Henderson facility with $10M capacity By Investing.com - Investing.com Canada
Vivos Therapeutics Opens New Henderson Sleep Center, Expects Capacity to More Than Double to Over $10 Million Annually - Quiver Quantitative
Vivos expects its Nevada sleep center to more than double annual capacity to $10M+ - Stock Titan
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... By GuruFocus - Investing.com Canada
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
Vivos Therapeutics stock falls 6% on second quarter revenue miss By Investing.com - Investing.com Canada
Vivos Therapeutics stock falls 6% on second quarter revenue miss - Investing.com
Conferencia de resultados del 2T de 2026 de Vivos Therapeutics (VVOS): los ingresos suben un 35%, persisten los riesgos de liquidez - TradingKey
Vivos Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Vivos Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Vivos gets Washington license to manufacture IsoPet - scanx.trade
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Vivos Therapeutics posts strong Q2 2026 revenue growth - Investing.com Canada
Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com - Investing.com Canada
Vivos Therapeutics Q2 revenue up 35%; targets positive cash flow by late 2026 - scanx.trade
Vivos Therapeutics reports 35% revenue increase in Q2 2026 - Investing.com
Vivos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivos Therapeutics Q2 revenue rises 35% on service growth - TradingView
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results - Quiver Quantitative
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update - Yahoo Finance
Vivos Therapeutics Inc (NASDAQ: VVOS) Share Price, VVOS Stock News, VVOS Share Price & Updates - Kalkine
Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics schedules Q2 2026 results, conference call - scanx.trade
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call - marketscreener.com
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn - Stock Titan
Vivos Therapeutics (VVOS) Edges Higher as Penny Stock Holds Support Near $0.29High Reward Trades - Vinanet
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices - TipRanks
Vivos Oral Appliance Shows Improvement in Insomnia Severity - Sleep Review
Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS) - Stock Titan
Vivos partners with Greenway Health to deploy AI platform - Investing.com
Vivos partners with Greenway Health to deploy AI platform By Investing.com - Investing.com Nigeria
Vivos Therapeutics Expands AI Workflow Partnership With Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Moomoo
Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Quiver Quantitative
Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada - Stock Titan
Vivos Therapeutics partners with Greenway Health for AI deployment - scanx.trade
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology - Yahoo Finance
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology - The Manila Times
Vivos sleep apnea devices gain broader protection after new patent - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market SessionBluejay Diagnostics (NASDAQ:BJDX), Ameri - Benzinga
Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market - Moomoo
Vivos Therapeutics (VVOS) Edges Up 1.71% to $0.42 as Stock Tests Range Between $0.40 Support and $0.44 ResistanceCovered Call Trade - dars.gov.et
Vivos Therapeutics appoints Roman Franklin as new CFO - scanx.trade
Vivos Therapeutics Inc (VVOS) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.75%
大文字化:
|
ボリューム (24 時間):